123 related articles for article (PubMed ID: 35443252)
1. PIM1 is a Poor Prognostic Factor for and Potential Therapeutic Target in Serous Carcinoma of the Endometrium.
Takeuchi H; Miyamoto T; Fuseya C; Asaka R; Ida K; Ono M; Tanaka Y; Shinagawa M; Ando H; Asaka S; Shiozawa T
Int J Gynecol Pathol; 2023 May; 42(3):282-292. PubMed ID: 35443252
[TBL] [Abstract][Full Text] [Related]
2. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
3. PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis.
Zhao B; Liu L; Mao J; Zhang Z; Wang Q; Li Q
Cell Death Dis; 2018 Feb; 9(3):307. PubMed ID: 29472550
[TBL] [Abstract][Full Text] [Related]
4. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.
Leung CO; Wong CC; Fan DN; Kai AK; Tung EK; Xu IM; Ng IO; Lo RC
Oncotarget; 2015 May; 6(13):10880-92. PubMed ID: 25834102
[TBL] [Abstract][Full Text] [Related]
5. PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway.
Cao L; Wang F; Li S; Wang X; Huang D; Jiang R
Cancer Lett; 2019 Mar; 444():116-126. PubMed ID: 30583073
[TBL] [Abstract][Full Text] [Related]
6. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
[TBL] [Abstract][Full Text] [Related]
7. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
8. PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression.
Xiang X; Yuan D; Liu Y; Li J; Wen Q; Kong P; Gao L; Zhang C; Gao L; Peng X; Zhang X
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):800-806. PubMed ID: 30020405
[TBL] [Abstract][Full Text] [Related]
9. TAB3 upregulates PIM1 expression by directly activating the TAK1-STAT3 complex to promote colorectal cancer growth.
Li Q; Chen L; Luo C; ChenYan ; Ge J; Zhu Z; Wang K; Yu X; Lei J; Liu T; Peng X; Liu X; Yuan R
Exp Cell Res; 2020 Jun; 391(1):111975. PubMed ID: 32229191
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biological significance of PIM1 kinase in osteosarcoma.
Liao Y; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
J Orthop Res; 2016 Jul; 34(7):1185-94. PubMed ID: 26687194
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
12. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.
Zippo A; De Robertis A; Serafini R; Oliviero S
Nat Cell Biol; 2007 Aug; 9(8):932-44. PubMed ID: 17643117
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion.
Eerola SK; Santio NM; Rinne S; Kouvonen P; Corthals GL; Scaravilli M; Scala G; Serra A; Greco D; Ruusuvuori P; Latonen L; Rainio EM; Visakorpi T; Koskinen PJ
Cell Commun Signal; 2019 Nov; 17(1):148. PubMed ID: 31730483
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.
Ha S; Iqbal NJ; Mita P; Ruoff R; Gerald WL; Lepor H; Taneja SS; Lee P; Melamed J; Garabedian MJ; Logan SK
Oncogene; 2013 Aug; 32(34):3992-4000. PubMed ID: 22986532
[TBL] [Abstract][Full Text] [Related]
16. RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.
van der Meer R; Song HY; Park SH; Abdulkadir SA; Roh M
Clin Cancer Res; 2014 Jun; 20(12):3211-21. PubMed ID: 24771642
[TBL] [Abstract][Full Text] [Related]
17. PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells.
Kim W; Youn H; Kwon T; Kang J; Kim E; Son B; Yang HJ; Jung Y; Youn B
Pharmacol Res; 2013 Apr; 70(1):90-101. PubMed ID: 23352980
[TBL] [Abstract][Full Text] [Related]
18. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
19. PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation.
Gao X; Liu X; Lu Y; Wang Y; Cao W; Liu X; Hu H; Wang H
Breast Cancer; 2019 Sep; 26(5):663-671. PubMed ID: 30989585
[TBL] [Abstract][Full Text] [Related]
20. PIM1: a promising target in patients with triple-negative breast cancer.
Zhao W; Qiu R; Li P; Yang J
Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
